Achieve Life Sciences, Inc. (ACHV)
7.66
-0.18
(-2.30%)
USD |
NASDAQ |
Sep 09, 10:55
Achieve Life Sciences Enterprise Value : 632.95M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 632.95M |
| September 04, 2026 | 699.71M |
| September 03, 2026 | 681.22M |
| September 02, 2026 | 698.69M |
| September 01, 2026 | 675.06M |
| August 31, 2026 | 643.22M |
| August 28, 2026 | 659.65M |
| August 27, 2026 | 667.87M |
| August 26, 2026 | 677.12M |
| August 25, 2026 | 666.84M |
| August 24, 2026 | 643.22M |
| August 21, 2026 | 648.36M |
| August 20, 2026 | 651.44M |
| August 19, 2026 | 703.82M |
| August 18, 2026 | 600.08M |
| August 17, 2026 | 598.02M |
| August 14, 2026 | 607.27M |
| August 13, 2026 | 572.34M |
| August 12, 2026 | 514.82M |
| August 11, 2026 | 523.04M |
| August 10, 2026 | 512.77M |
| August 07, 2026 | 510.71M |
| August 06, 2026 | 500.44M |
| August 05, 2026 | 511.74M |
| August 04, 2026 | 492.23M |
| Date | Value |
|---|---|
| August 03, 2026 | 476.82M |
| July 31, 2026 | 487.09M |
| July 30, 2026 | 474.76M |
| July 29, 2026 | 461.92M |
| July 28, 2026 | 462.44M |
| July 27, 2026 | 462.44M |
| July 24, 2026 | 454.22M |
| July 23, 2026 | 461.41M |
| July 22, 2026 | 475.79M |
| July 21, 2026 | 495.31M |
| July 20, 2026 | 468.60M |
| July 17, 2026 | 471.68M |
| July 16, 2026 | 439.84M |
| July 15, 2026 | 477.84M |
| July 14, 2026 | 475.79M |
| July 13, 2026 | 454.22M |
| July 10, 2026 | 455.25M |
| July 09, 2026 | 485.04M |
| July 08, 2026 | 465.52M |
| July 07, 2026 | 497.36M |
| July 06, 2026 | 490.17M |
| July 02, 2026 | 485.04M |
| July 01, 2026 | 485.04M |
| June 30, 2026 | 498.39M |
| June 29, 2026 | 317.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 268.42M |
| Perspective Therapeutics, Inc. | 123.04M |
| MiMedx Group, Inc. | 561.90M |
| ProText Mobility, Inc. | 30.96M |
| ABVC BioPharma, Inc. | 32.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -74.77M |
| Total Expenses (Quarterly) | 74.77M |
| EPS Diluted (Quarterly) | -0.7996 |
| Earnings Yield | -20.21% |
| Normalized Earnings Yield | -14.60 |